Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Scientists Engineer Antibiotics in Race Against Drug Resistance

September 30, 2014 2:56 pm | News | Comments

We face an urgent global health problem because scientists are not developing new antibiotics as fast as bacteria are developing antibiotic resistance. But new research from UCLA has made important progress toward solving this problem. Read more...

TOPICS:

Engineers Devise Technology for Rapidly Testing Drug-Delivery Vehicles

September 30, 2014 2:43 pm | News | Comments

Engineers have devised a way to rapidly test hundreds of different drug-delivery vehicles in living animals, making it easier to discover promising new ways to deliver a class of drugs called biologics, which includes antibodies, peptides, RNA, and DNA, to human patients. Read more...

TOPICS:

Testing Cancer Drugs' Benefit for Individual Patients

September 30, 2014 2:28 pm | News | Comments

An official at a life sciences startup based on a Purdue University innovation says his company may help oncologists see faster than ever which drug therapies will benefit cancer patients and to what extent. Read more...         

TOPICS:
Advertisement

Viagra Ads Target Women for First Time

September 30, 2014 1:52 pm | by Linda Johnson, AP Business Writer | News | Comments

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women. Read more...

TOPICS:

Sanofi, Regeneron Announce Positive Dupilumab Results

September 30, 2014 11:00 am | News | Comments

Regeneron Pharmaceuticals and Sanofi announced that a Phase 2a study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. Read more...

TOPICS:

Pfizer, Kyowa Hakko Kirin Partner on Immuno-Oncology Combo Study

September 30, 2014 10:49 am | News | Comments

Pfizer Inc. and Kyowa Hakko Kirin announced that they've entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read more...         

TOPICS:

NIH Awards Seven New Vaccine Adjuvant Discovery Contracts

September 30, 2014 10:37 am | News | Comments

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability. Read more...

TOPICS:

Gov't to Reveal Drug Company Payments to Doctors

September 30, 2014 10:27 am | by Ricardo Alonso-Zaldivar | News | Comments

Striving to shine a light on potential ethical conflicts in medicine, the Obama administration is releasing data on drug company payments to tens of thousands of individual doctors. Read more...                

TOPICS:
Advertisement

Ebola Labs, Parts for Clinic Arrive in Liberia

September 30, 2014 10:15 am | by Jonathan Paye-Layleh | News | Comments

U.S. mobile Ebola labs should be up and running in Liberia this week, and American troops have broken ground for a field hospital, as the international community races to increase the ability to care for the spiraling number of people infected with the dreaded disease. Read more...

TOPICS:

Takeda, Seattle Genetics Receive Positive Data from Lymphoma Trial

September 30, 2014 10:02 am | News | Comments

Seattle Genetics and Takeda Pharmaceutical Co. Ltd. announced that patients with Hodgkin lymphoma (HL) who received Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) lived significantly longer without disease progression compared to patients who received placebo. Read more...

TOPICS:

Array's Melanoma Drug Promising in Phase 2

September 29, 2014 3:46 pm | News | Comments

Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2. Read more...

TOPICS:

Tonix Fibromyalgia Pain Drug Misses Endpoint in Phase 2b

September 29, 2014 3:28 pm | News | Comments

Tonix Pharmaceuticals announced results of the Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12. Read more...

TOPICS:

Insys Therapeutics' Cannabidiol Receives FDA Orphan Drug Designation

September 29, 2014 3:23 pm | News | Comments

Insys Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioma. Read more...             

TOPICS:

Amag Pharma to Acquire Lumara Health for $675M

September 29, 2014 3:09 pm | News | Comments

Shares of anemia treatment maker Amag Pharmaceuticals soared Monday after it announced plans to buy Lumara Health in a cash-and-stock deal that eventually could be worth more than $1 billion. Read more...             

TOPICS:

Combo Treatment Ups PFS in Advanced Melanoma Patients

September 29, 2014 3:07 pm | News | Comments

Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading